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Abstract
Background: Human and canine leishmaniasis (CanL) by Leishmania infantum is endemic in Italy,
with a high percentage of infected asymptomatic animals. However, the immune response
mechanisms underlying the clinical presentation of CanL have not been fully investigated. Among
leishmanicidal molecules produced by activated macrophages, nitric oxide (NO) produced by an
inducible NO synthase seems to play an important protective role, but no conclusive data are
available. Therefore, NO released by cultured macrophages from dogs with natural Leishmania
infection living in an endemic area for CanL was evaluated.
Methods: On the basis of one year's clinical and laboratory follow-up, 22 dogs infected by
Leishmania infantum were identified and grouped as: asymptomatic dogs (n = 13) and dogs with
symptoms of leishmaniasis (n = 9). Each animal was bled twice at 4-month intervals and macrophage
and lymphocyte cultures were obtained from peripheral blood mononuclear cells. Supernatants of
L. infantum-infected macrophage cultures, with or without addition of autologous lymphocytes,
were assayed for NO production by Griess reaction for nitrites.
Results: In the first months of the infection the levels of NO in supernatants of Leishmania-infected
macrophages were higher in symptomatic than in asymptomatic dogs, but they were significantly
increased in the latter group eight months after the diagnosis of infection. Furthermore, NO
release significantly decreased in the presence of autologous lymphocytes in both groups of animals.
Conclusion: These results suggest that NO may be involved in the long-term protection of dogs
against natural Leishmania infection and in the clinical presentation of canine leishmaniasis in the
Mediterranean area.
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Background
Protozoa of the Leishmania  genus infect mononuclear
phagocytes of several mammalian species, including dogs,
in which they often give rise to a chronic, non self-healing
visceral disease [1]. The dog is the main competent and
reservoir host for Leishmania infantum in the Mediterra-
nean Basin, Middle East and Central Asia up to Pakistan
and China, of L. chagasi in Central and South America and
of L. peruviana in the Peruvian Andes [2,3]. In addition, its
role as a reservoir was indicated for L. donovani in Eastern
Sudan and Morocco, and for L. tropica in Iran and proba-
bly in Northern Africa [4]. Human leishmaniasis has
recently been categorised as an emerging and uncon-
trolled disease (i.e. category 1), with a total disease burden
of 2,090,000 Disability-Adjusted Life-Years (DALYs) and
51,000 deaths per year [5].
Human and canine leishmaniasis (CanL) from Leishmania
infantum zymodeme MON-1 is endemic in Central and
Southern regions of Italy as well as the islands [6]. In
recent years, a rapid increase of autochthonous cases of
CanL has been recorded also in Northern Italian regions
as a consequence of the spread of suitable habitats for the
sandfly vector [7]. In the Apulia region (Southern Italy) a
yearly incidence rate of CanL of about 9.52% has been
estimated in both farm and kennel dogs [8], with a high
percentage (53.1%) of serologically positive asympto-
matic animals [9]. In fact, these dogs display either
asymptomatic or symptomatic parasitism, the latter rang-
ing from limited to multifocal tissue damage with or with-
out hypergammaglobulinaemia. Transmission of
Leishmania spp. occurs when phlebotomine sandfly vec-
tors feed on infected dogs, either symptomatic or asymp-
tomatic [10], so both groups of animals are significant for
the transmission of human and CanL. This highlights the
importance of dogs in spreading human disease, also in
the light of a possibly prolonged subpatent period [11].
Control measures for CanL include evaluation of new
diagnostic tests [12], reliable screening of new com-
pounds for chemotherapy [13], zoonotic reservoir con-
trol, including insecticide-based preparations for dog
protection [14,15], and development of an affordable and
effective vaccine for dogs [reviewed by [1]]. Under these
circumstances, a knowledge of the immune mechanisms
involved in animal protection plays a pivotal role in
understanding the pathogenesis and clinical progression
of the disease, as well as in the development of vaccines.
Among leishmanicidal molecules produced by interferon
(IFN)-γ-activated macrophages, nitric oxide (NO) pro-
duced by an inducible NO synthase (i.e. iNOS or NOS2)
seems to play an important protective role [16], which is
of interest also for CanL. Indeed, dog macrophages
infected in vitro by L. infantum promastigotes produced
NO after stimulation with cytokine-enriched peripheral
blood mononuclear cell (PBMC) supernatants [17] and
expressed NOS2, after stimulation with IFN-γ and bacte-
rial lipopolysaccharide (LPS) [18]. However, the immune
response mechanisms underlying the clinical presenta-
tion of CanL (i.e. in asymptomatic and symptomatic ani-
mals) have not been fully investigated and no conclusive
data are available concerning the role played by NO in
this context. Moreover, data on NO release by macro-
phages available from laboratory investigations on a
murine model [19] may be quite different from what hap-
pens under field conditions in naturally infected dogs.
This study has investigated for the first time if NO released
by activated macrophages from naturally infected dogs,
estimated by the nitrite content in the culture supernatant,
may play a role in the asymptomatic parasitism displayed
by dogs in Southern Italy.
Methods
Animal sampling and clinical examination
The animals came from two kennels in the Apulian
region, southern Italy (latitude 42° and 39° North, longi-
tude 15° and 18° East), where endemic CanL had been
reported over the previous years [8]. A total of 22 dogs
that were negative for L. infantum (at parasitological and
serological tests, see below) in March 2005 but resulted
newly infected by L. infantum in March 2006 (after one
sandfly season) were enrolled in the study. All selected
animals were positive at parasitological (i.e. PCR on skin
biopsy and/or microscopic examination of lymph node
smears) and/or serological tests for Leishmania [15] but
did not exhibit clinical symptoms or laboratory abnor-
malities of leishmaniasis.
During follow-up, clinical examination of dogs was per-
formed monthly, in order to evaluate a possible disease
progression. At 4 and 8 months follow-up visits from the
first diagnosis of Leishmania  infection (i.e. July and
November 2006), 20 mL heparinized peripheral blood
samples were obtained from each dog. Animals were han-
dled and sampled with the owners' consent and approval
by the Ethics Committee of the University of Bari.
Parasites
Parasites were isolated from the bone marrow of a Leish-
mania-infected dog and cultured on Tobie-Evans medium
at 24°C. The isolated strain was typed by the Istituto Supe-
riore di Sanità (Rome, Italy) and belonged to the L. infan-
tum species, zymodeme MON1. Promastigotes at day 4 of
culture were used, since the maximum percentage of met-
acyclic (virulent) promastigotes is detected on the 4th day
of growth for Leishmania infantum [20]. The liquid phase
of the tubes was collected and centrifuged at 350 g for 10
min. Supernatants were then discarded and the pellets
were suspended in phosphate buffered saline (PBS), pHParasites & Vectors 2008, 1:10 http://www.parasitesandvectors.com/content/1/1/10
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7.2 and washed 3 times by centrifugation at 350 g for 10
min. Finally, promastigotes were counted after immobili-
zation by 2–3 drops of 70% ethanol.
Isolation of peripheral blood mononuclear cells (PBMC)
PBMC were isolated from 20 mL of heparinized periph-
eral blood, diluted with sterile Hanks' balanced salt solu-
tion (HBSS; Gibco-Invitrogen, Carlsbad, CA, USA) at a 1:1
(v/v) ratio and centrifuged on the cell separation medium
Lympholyte-H (CEDARLANE, Burlington, Ontario, Can-
ada) at 700 g for 15 min at room temperature. Then, iso-
lated PBMC were extensively washed and suspended in
RPMI 1640 complete medium, supplemented with 2 mM
glutamine, 10% heat-inactivated (56°C for 30 min) foetal
calf serum (FCS), 100 μg/mL streptomycin and 100 IU/
mL penicillin. Cell viability was evaluated by trypan blue
dye exclusion and resulted greater than 98%. Isolated cells
were cultured at a density of 1 × 106/mL in 4-well microc-
ulture plates (Nunc, Roskilde, Denmark), at 37°C, 5%
CO2  for 24 h to permit monocyte adherence. Lym-
phocytes-enriched supernatants were then collected and
cultured in complete RPMI.
Macrophage culture, infection and treatment procedures
After 24 h of incubation, adherent mononuclear cells (1 ×
106/mL for each well) were washed-out three times with
HBSS and then incubated in fresh complete medium for 8
days to permit the differentiation of monocytes into mac-
rophages. During this period the medium was replaced
every 48–72 h. Cell viability determined by trypan blue
exclusion was greater than 98%. Morphological features
such as increased size, the presence of short, blunt pseu-
dopodia and non specific esterase staining showed that
more than 96% of the cells were macrophages.
After 8 days of adherence, macrophages were counted by
direct immunofluorescence for the CD16 macrophage
marker, using a FITC-labelled anti-CD16 monoclonal
antibody (Becton-Dickinson, USA), and 2,5 × 105CD16+
cells were infected with living L. infantum promastigotes
(1:3 cell/parasite ratio). After 24 h, infected macrophages
were gently washed to remove non-ingested parasites,
monitored by FITC-labelled anti-CD16 monoclonal anti-
body to ensure that no macrophages were lost when
washing the culture and then cultured for 48 h, in the
presence or absence of autologous lymphocytes (5 × 105/
mL for each well), which were separately cultured – once
depleted of adherent cells. Untreated uninfected macro-
phages were used as controls. In preliminary experiments
the number of macrophages engulfing parasites was eval-
uated. For this assay, macrophages (1 × 106/mL) were
incubated at 37°C in a 5% CO2 humidified atmosphere
with metacyclic Leishmania promastigotes at a 1:3 cell/par-
asite ratio for 48 h. At the end of the incubation periods,
cells were collected from the plates by detachment after
the addition of cold (+4°C) medium and vigorous aspira-
tion. Cells were then washed with PBS pH 7.2, cytocentri-
fuged onto glass slides and stained with methanol-Giemsa
stain. The phagocytosis percentage of macrophages was
microscopically calculated by counting the percentage of
cells containing at least one amastigote/300 cells and
resulted 84.6 ± 0.9, being the mean ± SD of three separate
experiments.
NO production evaluation
The concentration of nitrite (NO2-) released by macro-
phages determined by the Griess reaction was used as an
indicator of NO production. Briefly, after 72 h of infec-
tion, cell culture supernatants from macrophages were
mixed with an equal volume of Griess reagent, as
described by Ding and colleagues [21]. Experiments were
also performed in the presence of 200 μM L-NG-mono-
methylarginine (L-NGMMA, Sigma-Aldrich), a competi-
tive inhibitor of the iNOS, in order to assess whether NO
production is dependent upon iNOS activation. The
absorbance was spectrophotometrically measured at 540
nm and the NO2- concentration was determined by a
standard curve of NaNO2 and expressed as nmol/mL. To
avoid interference by any nitrites present in the medium,
the medium employed for the macrophage cultures was
used as blank.
Statistical analysis
Results were statistically examined by analysis of variance
(one-way ANOVA) and a p-value < 0.05 was considered
statistically significant.
Results
Of the 22 infected dogs initially tested, 13 remained
asymptomatic at four and eight months of follow-up,
while 9 showed one or more symptoms of leishmaniasis
(i.e. dermatitis, lymphadenopathy, conjunctivitis, skin
ulcers) and/or hypergammaglobulinemia. At the first fol-
low up (i.e. after four months from the first diagnosis of
Leishmania  infection), PBMC-derived macrophages
infected in vitro by L. infantum produced a significantly
higher amount of NO (p < 0.001) than macrophages not
infected in vitro, used as controls. In addition, the levels of
NO in supernatants of Leishmania-infected macrophages
were significantly higher (p < 0.001) in symptomatic vs
asymptomatic dogs (Fig. 1). Moreover, the addition of
autologous lymphocytes significantly (p < 0.001)
decreased NO production only in symptomatic dogs.
On the contrary, at the second follow-up (i.e. eight
months from the diagnosis of Leishmania infection), NO
released from Leishmania-infected macrophages, was sig-
nificantly higher (p < 0.001) in asymptomatic vs sympto-
matic dogs (Fig. 2). As in the samples taken after 4
months, this production was significantly (p < 0.001)Parasites & Vectors 2008, 1:10 http://www.parasitesandvectors.com/content/1/1/10
Page 4 of 7
(page number not for citation purposes)
lower in supernatants from uninfected macrophages used
as control. Results from macrophages co-cultured with
autologous lymphocytes showed that NO production was
significantly reduced in Leishmania-infected macrophages
both in asymptomatic and symptomatic dogs (p < 0.001
and p < 0.05, respectively) (Fig. 2).
In order to investigate a possible variation in NO produc-
tion during the course of the infection, results obtained
after four and eight months were compared. Figure 3
shows that in infected macrophage supernatants from
asymptomatic dogs, NO production was significantly
increased (p < 0.001) after eight months, in comparison
with samples taken after four months. Also in these exper-
iments, co-incubation of infected macrophages with
autologous lymphocytes significantly decreased NO pro-
duction. Interestingly, in dogs that developed symptoms,
no increase in NO production by infected macrophages
was observed in samples obtained after eight months in
comparison with those taken after four months from diag-
nosis of the infection.
Finally, macrophage stimulation in the presence of the L-
arginine analogue NO synthase inhibitor (L-NGMMA)
caused a reduction of NO production at basal levels, thus
confirming that NO production in infected cells was
induced by iNOS activation (data not shown).
Discussion
The NO production by cultured PBMC-derived macro-
phages has been investigated herein for the first time in
both symptomatic and asymptomatic dogs with natural
Leishmania infection. Results of this study demonstrated
that: i) NO release from macrophages was enhanced by in
vitro infection; ii) in the first months of the infection the
NO release by L. infantum-infected macrophages from  asymptomatic (left) and symptomatic (right) dogs at four and  eight months after diagnosis of Leishmania infection Figure 3
NO release by L. infantum-infected macrophages 
from asymptomatic (left) and symptomatic (right) 
dogs at four and eight months after diagnosis of 
Leishmania infection. A, macrophages without lym-
phocytes (4 months); B, macrophages incubated with autolo-
gous lymphocytes (4 months); C, macrophages without 
lymphocytes (8 months); D, macrophages with autologous 
lymphocytes (8 months). Results are expressed as means ± 
SE.
NO release by monocyte-derived macrophages four months  after the diagnosis of Leishmania infection Figure 1
NO release by monocyte-derived macrophages four 
months after the diagnosis of Leishmania infection. 
CTL: uninfected macrophages (controls). LEISH: L. infan-
tum-infected macrophages. A, macrophages from sympto-
matic dogs incubated without lymphocytes; B, macrophages 
from symptomatic dogs incubated in presence of autologous 
lymphocytes; C, macrophages from asymptomatic dogs incu-
bated without autologous lymphocytes; D, macrophages 
from asymptomatic dogs incubated with autologous lym-
phocytes. Results are expressed as means ± SE.
NO release by monocyte-derived macrophages eight months  after diagnosis of Leishmania infection Figure 2
NO release by monocyte-derived macrophages eight 
months after diagnosis of Leishmania infection. CTL: 
uninfected macrophages (controls). LEISH: L. infantum-
infected macrophages. A, macrophages from symptomatic 
dogs incubated without lymphocytes; B, macrophages from 
symptomatic dogs incubated with autologous lymphocytes; 
C, macrophages from asymptomatic dogs without lym-
phocytes; D, macrophages from asymptomatic dogs with 
autologous lymphocytes. Results are expressed as means ± 
SE.Parasites & Vectors 2008, 1:10 http://www.parasitesandvectors.com/content/1/1/10
Page 5 of 7
(page number not for citation purposes)
levels of NO in supernatants of Leishmania-infected mac-
rophages were higher in symptomatic than in asympto-
matic dogs, but significantly increased in the latter group
after eight months from the diagnosis of Leishmania infec-
tion; iii) co-culture of macrophages with autologous lym-
phocytes reduced NO production especially in
symptomatic dogs.
In the light of these results, it is possible that cells
obtained from symptomatic animals are pre-activated in
vivo, and hence that infection of these cells in vitro pro-
vides a secondary stimulus that results in NO release.
According to this reasoning, NO production at the begin-
ning of infection might be an indicator of immune activity
in infected animals but not an indicator of resistance.
However, the higher levels of NO observed in follow-up
in symptom-free animals may also suggest a protective
role for this molecule in the long term asymptomatic
parasitism displayed by dogs in Southern Italy. The aug-
mented NO production in these animals may be due to
cytokines such as IFN-γ and tumor necrosis factor (TNF)-
α, which exert an activating effect on iNOS and regulate
the enzyme at both the transcriptional and post-transcrip-
tional levels [22].
The involvement of NO in protecting against CanL has
already been demonstrated by inducing antileishmanial
macrophage activity via the L-arginine NO pathway [23].
In addition, an increased NO production and anti-leish-
manial activity of infected cells was demonstrated using
canine macrophages activated by a supernatant derived
from a Leishmania-specific T cell line which contained
IFN-γ, TNF-α and IL-2 [24]. The role played by NO in par-
asitocidal activity has also been investigated in the context
of vaccination studies. It was found that the amount of
IFN-γ in dog PBMC supernatants and NO production by
macrophages increased after administration of a killed L.
infantum promastigote vaccine [25]. In another study, vac-
cine-induced protection correlated with a Th1-type cellu-
lar immune response specifically directed against purified
excreted-secreted antigens from L. infantum promastigotes
(LiESAp), including: i) an enhanced NO-mediated anti-
leishmanial activity of dog macrophages co-cultured with
IFN-γ producing autologous lymphocytes [26] and ii)
NO-mediated apoptosis of intracellular amastigotes in
canine macrophages [27]. The above results have also
been confirmed under field conditions, with a signifi-
cantly enhanced NO-mediated anti-leishmanial macro-
phage activity almost exclusively revealed in vaccinated
animals [28]. In a separate study carried out in Brazil,
PBMC supernatants from dogs immunized with promas-
tigote lysates and infected with L. chagasi were also able to
stimulate the parasitocidal activity of macrophages in
healthy dogs, through NO production [29]. Several cellu-
lar targets may be subject to NO toxicity in Leishmania par-
asites, including enzymes of glycolysis and respiratory
metabolism, as well as trans-membrane transport systems
[30].
Moreover, exposure of amastigotes to moderate concen-
trations of donor NO or to endogenous NO produced by
macrophages resulted in cell death, with extensive frag-
mentation of nuclear DNA, in both axenic and intracellu-
lar amastigotes of L. amazonensis [31]. NO is also involved
in the parasitocidal effect of anti-Leishmania drugs. In fact,
sodium antimony gluconate treatment induces murine
macrophages activation of the p38 MAPK signalling path-
way, with subsequent TNF-α release, NO production and
NO-dependent parasite killing [32]. Moreover, SbIII-
resistant amastigotes were also resistant to NO toxicity
when delivered extracellularly via NO donors or intracel-
lularly via macrophage activation [33].
In the present study addition of autologous lymphocytes
reduced NO production in co-cultured macrophages.
Which cell fraction of PBMCs was responsible for this sup-
pression is an area requiring further investigation, also
using commercially available dog CD markers. Moreover,
the decreased NO release in the presence of autologous
lymphocytes suggests a likely role for anti-inflammatory
cytokines (e.g. IL-4, IL-10, IL-13) and transforming
growth factor (TGF)-β, released by lymphocytes of Leish-
mania infected animals, whose inhibitory effect on signal
transduction for iNOS and NO production was previously
described in macrophages and other cells in different ani-
mal models [22,34]. Although the relationship between
anti-inflammatory cytokines and NO production in dogs
deserves further investigation, the production of these
cytokines in canine Leishmania infection has already been
demonstrated, like TGF-β1 and IL-10 in the spleen and
liver of both symptomatic and asymptomatic dogs natu-
rally infected by L. chagasi [35], and IL-4 expression in
skin biopsies [36] and in spleen [37] of L. infantum-
infected dogs.
Conclusion
Overall, the results of this paper suggest that: i) NO could
be strongly involved in the long-term protection of dogs
against natural L. infantum infection and in the clinical
presentation of leishmaniasis in the Mediterranean area,
and ii) autologous lymphocytes may exert an inhibitory
effect on NO production by macrophages from naturally-
infected animals. These results may contribute to a better
understanding of the pathogenesis and clinical course of
CanL in endemic areas, helping to develop control strate-
gies both for human and canine leishmaniasis.
Competing interests
The authors declare that they have no competing interests.Parasites & Vectors 2008, 1:10 http://www.parasitesandvectors.com/content/1/1/10
Page 6 of 7
(page number not for citation purposes)
Authors' contributions
PMA conceived of the study, participated in its design and
coordination and helped to draft the manuscript. BO par-
ticipated in the study design and drafted the manuscript.
dCD participated in animal sampling and clinical exami-
nation. CP carried out cell culture studies. CA participated
in cell culture experiments and performed the statistical
analysis. MV participated in the study design and coordi-
nation. OD participated in the study design and coordina-
tion and helped to draft the manuscript. All authors read
and approved the final manuscript.
Acknowledgements
This research has been partially supported by the University of Bari (funds 
"Ateneo 2007") and by Bayer Animal Health (Germany). The authors thank 
Ms. Mary Pragnell, B.A. for English revision.
References
1. Barbieri CL: Immunology of canine leishmaniasis.  Parasite
Immunol 2006, 28:329-337.
2. Dantas-Torres F: The role of dogs as reservoirs of Leishmania
parasites, with emphasis on Leishmania (Leishmania) infan-
tum and Leishmania (Viannia)  braziliensis.  Vet Parasitol 2007,
149:139-146.
3. Marty P, Izri A, Ozon C, Haas P, Rosenthal E, Del Giudice P, Godenir
J, Coulibaly E, Gari-Toussaint M, Delaunay P, Ferrua B, Haas H, Prat-
long F, Le Fichoux Y: A century of leishmaniasis in Alpes-Mari-
times, France.  Ann Trop Med Parasitol 2007, 101:563-574.
4. Gramiccia M, Gradoni L: The current status of zoonotic leish-
maniases and approaches to disease control.  Int J Parasitol
2005, 35:1169-1180.
5. TDR Disease Portfolio   [http://www.who.int/tdr/diseases/
default.htm]
6. Mannocci A, La Torre G, Chiaradia G, De Waure C, Mainelli MT,
Cernigliaro A, Bruno S, Ricciardi W: Epidemiology and direct
medical costs of human leishmaniasis in Italy.  J Prev Med Hyg
2007, 48:27-36.
7. Capelli G, Baldelli R, Ferroglio E, Genchi C, Gradoni L, Gramiccia M,
Maroli M, Mortarino M, Pietrobelli M, Rossi L, Ruggiero M: Monitor-
ing of canine leishmaniasis in northern Italy: an update from
a scientific network.  Parassitologia 2004, 46:193-197.
8. Paradies P, Capelli G, Cafarchia C, de Caprariis D, Sasanelli M,
Otranto D: Incidences of canine leishmaniasis in an endemic
area of southern Italy.  J Vet Med B Infect Dis Vet Public Health 2006,
53(6):295-298.
9. Brandonisio O, Carelli G, Ceci L, Consenti B, Fasanella A, Puccini V:
Canine leishmaniasis in the Gargano promontory (Apulia,
South Italy).  Eur J Epidemiol 1992, 8:273-276.
10. Molina R, Amela C, Nieto J, San-Andrés M, González F, Castillo JA,
Lucientes J, Alvar J: Infectivity of dogs naturally infected with
Leishmania infantum to colonized Phlebotomus perniciosus.
Trans R Soc Trop Med Hyg 1994, 88:491-493.
11. Oliva G, Scalone A, Foglia Manzillo V, Gramiccia M, Pagano A, Di Muc-
cio T, Gradoni L: Incidence and time course of Leishmania
infantum infections examined by parasitological, serologic,
and nested-PCR techniques in a cohort of naive dogs
exposed to three consecutive transmission seasons.  J Clin
Microbiol 2006, 44:1318-1322.
12. Otranto D, Paradies P, Sasanelli M, Leone N, de Caprariis D, Chirico
J, Spinelli R, Capelli G, Brandonisio O: Recombinant K39 dipstick
immunochromatographic test: a new tool for the serodiag-
nosis of canine leishmaniasis.  J Vet Diagn Invest 2005, 17:32-37.
13. Fumarola L, Spinelli R, Brandonisio O: In vitro assays for evalua-
tion of drug activity against Leishmania spp.  Res Microbiol 2004,
155:224-230.
14. Maroli M, Mizzoni V, Siragusa C, D'Orazi A, Gradoni L: Evidence for
an impact on the incidence of canine leishmaniasis by the
mass use of deltamethrin-impregnated dog collars in South-
ern Italy.  Med Vet Entomol 2001, 15:358-363.
15. Otranto D, Paradies P, Lia RP, Latrofa MS, Testini G, Cantacessi C,
Mencke N, Galli G, Capelli G, Stanneck D: Efficacy of a combina-
tion of 10% imidacloprid/50% permethrin for the prevention
of leishmaniasis in kennelled dogs in an endemic area.  Vet Par-
asitol 2007, 144:270-278.
16. Mauël J, Ransijn A, Buchmüller-Rouiller Y: Killing of Leishmania
parasites in activated murine macrophages is based on an L-
arginine-dependent process that produces nitrogen deri-
vates.  J Leuk Biol 1991, 49:73-82.
17. Panaro MA, Fasanella A, Lisi S, Mitolo V, Andriola A, Brandonisio O:
Evaluation of nitric oxide production by Leishmania infantum-
infected dog macrophages.  Immunopharmacol Immunotoxicol
1998, 20:147-158.
18. Sisto M, Brandonisio O, Panaro MA, Acquafredda A, Leogrande D,
Fasanella A, Trotta T, Fumarola L, Mitolo V: Inducible nitric oxide
synthase expression in Leishmania-infected dog macro-
phages.  Comp Immunol Microbiol Infect Dis 2001, 24:247-54.
19. Kima PE: The amastigote forms of Leishmania are experts at
exploiting host cell processes to establish infection and per-
sist.  Int J Parasitol 2007, 37:1087-1096.
20. Louassini M, Adroher FJ, Foulquie MR, Benitez R: Investigations on
the in vitro metacyclogenesis of a visceral and a cutaneous
human strain of Leishmania infantum.  Acta Trop 1998,
70:355-368.
21. Ding AH, Nathan CF, Stuehr DJ: Release of reactive nitrogen
intermediates and reactive oxygen intermediates from
mouse peritoneal macrophages. Comparison of activating
cytokines and evidence for independent production.  J Immu-
nol 1988, 141:2407-2412.
22. Bogdan C, Röllinghoff M, Diefenbach A: Reactive oxygen and
reactive nitrogen intermediates in innate and specific immu-
nity.  Curr Opin Immunol 2000, 12:64-76.
23. Vouldoukis I, Drapier JC, Nussler AK, Tselentis Y, Da Silva OA, Gen-
tilini M, Mossalayi DM, Monjour L, Dugas B: Canine visceral leish-
maniasis: successful chemotherapy induces macrophage
antileishmanial activity via the L-arginine nitric oxide path-
way.  Antimicrob Agents Chemother 1996, 40:253-256.
24. Pinelli E, Gebhard D, Mommaas AM, van Hoeij M, Langermans JA,
Ruitenberg EJ, Rutten VP: Infection of a canine macrophage cell
line with Leishmania infantum: determination of nitric oxide
production and anti-leishmanial activity.  Vet Parasitol 2000,
92:181-189.
25. Panaro MA, Acquafredda A, Lisi S, Lofrumento DD, Mitolo V, Sisto M,
Fasanella A, Trotta T, Bertani F, Consenti B, Brandonisio O: Nitric
oxide production by macrophages of dogs vaccinated with
killed Leishmania infantum promastigotes.  Comp Immunol Micro-
biol Infect Dis 2001, 24:187-195.
26. Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G,
Papierok G: Protection against experimental visceral leishma-
niasis infection in dogs immunized with purified excreted
secreted antigens of Leishmania infantum promastigotes.  Vac-
cine 2005, 23:2825-2840.
27. Holzmuller P, Cavaleyra M, Moreaux J, Kovacic R, Vincendeau P,
Papierok G, Lemesre JL: Lymphocytes of dogs immunised with
purified excreted-secreted antigens of Leishmania infantum
co-incubated with Leishmania  infected macrophages pro-
duce IFN-gamma resulting in nitric oxide-mediated amastig-
ote apoptosis.  Vet Immunol Immunopathol 2005, 106:247-257.
28. Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C,
Cavaleyra M, Papierok G: Long-lasting protection against
canine visceral leishmaniasis using the LiESAp-MDP vaccine
in endemic areas of France: double-blind randomised effi-
cacy field trial.  Vaccine 2007, 25:4223-4234.
29. Rodrigues CA, Batista LF, Teixeira MC, Pereira AM, Santos PO, de Sa
Oliveira GG, de Freitas LA, Veras PS: Peripheral blood mononu-
clear cell supernatants from asymptomatic dogs immunized
and experimentally challenged with Leishmania chagasi can
stimulate canine macrophages to reduce infection in vitro.
Vet Parasitol 2007, 143:197-205.
30. Mauël J, Ransijn A: Leishmania spp.: mechanisms of toxicity of
nitrogen oxidation products.  Exp Parasitol 1997, 87:98-111.
31. Holzmuller P, Sereno D, Cavaleyra M, Mangot I, Daulouede S, Vincen-
deau P, Lemesre JL: Nitric oxide-mediated proteasome-
dependent oligonucleosomal DNA fragmentation in Leish-
mania amazonensis amastigotes.  Infect Immun 2002,
70:3727-3735.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Parasites & Vectors 2008, 1:10 http://www.parasitesandvectors.com/content/1/1/10
Page 7 of 7
(page number not for citation purposes)
32. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Sen P, Banerjee S,
Naskar K, Choudhuri SK, Saha B, Raha S, Roy S: Sodium antimony
gluconate induces generation of reactive oxygen species and
nitric oxide via phosphoinositide 3-kinase and mitogen-acti-
vated protein kinase activation in Leishmania donovani-
infected macrophages.  Antimicrob Agents Chemother 2006,
50:1788-1797.
33. Holzmuller P, Sereno D, Lemesre JL: Lower nitric oxide suscepti-
bility of trivalent antimony-resistant amastigotes of Leishma-
nia infantum.  Antimicrob Agents Chemother 2005, 49:4406-4409.
34. Panaro MA, Brandonisio O, Acquafredda A, Sisto M, Mitolo V: Evi-
dences for iNOS expression and nitric oxide production in
the human macrophages.  Curr Drug Targets Immune Endocr
Metabol Disord 2003, 3:210-221.
35. Corrêa AP, Dossi AC, de Oliveira Vasconcelos R, Munari DP, de Lima
VM: Evaluation of transformation growth factor beta1, inter-
leukin-10, and interferon-gamma in male symptomatic and
asymptomatic dogs naturally infected by Leishmania (Leish-
mania) chagasi.  Vet Parasitol 2007, 143:267-274.
36. Brachelente C, Muller N, Doherr MG, Sattler U, Welle M: Cutane-
ous leishmaniasis in naturally infected dogs is associated with
a T helper-2-biased immune response.  Vet Pathol 2005,
42:166-175.
37. Strauss-Ayali D, Baneth G, Jaffe CL: Splenic immune responses
during canine visceral leishmaniasis.  Vet Res 2007, 38:547-564.